Black patients more likely to experience MACE after ADT for prostate cancer

Black patients are more likely to experience adverse cardiovascular outcomes after systemic androgen deprivation therapy (ADT) for prostate cancer, according to a study published online June 18 in JACC: CardioOncology. Biniyam G. Demissei, M.D., from the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, and colleagues conducted a retrospective cohort study involving 3,543 prostate cancer patients treated with systemic ADT between 2008 and 2021. The multivariable adjusted association between self-reported race (Black versus White) and incident major adverse cardiovascular events (MACE) after initiation of ADT was assessed. Read More

Related posts:

  1. Researchers complete first trial of Black patients with early-stage breast cancer
  2. Research reports improvements in survival rates in patients with metastatic prostate cancer
  3. Study finds 1 in 12 patients labeled as having ‘benign’ results actually had high-risk prostate cancer
  4. Novel liquid biopsy methodology enables monitoring of disease evolution in patients with metastatic prostate cancer
  5. Ultrasounds may not find this cancer in Black women
  6. Preventing cancer for future generations of Black families
  7. More than 1 in 10 patients at federally qualified health centers experience major social risk factors
  8. AI model may yield better outcomes for prostate cancer

Leave a Reply

Your email address will not be published. Required fields are marked *